Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy

Han, Wenbo; Duan, Xiaopin; Ni, Kaiyuan; Li, Youyou; Chan, Cheeling; Lin, Wenbin

doi:10.1016/j.biomaterials.2021.121315

Cited by 67 publications

(30 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…designed core-shell nanoparticles (ZnP@DHA/Pyro-Fe) loaded with a cholesterol derivative of dihydroartemisinin and pyropheophorbide-iron (Pyro-Fe) to potentiate CRC immunotherapy via inducing ferroptosis. ZnP@DHA/Pyro-Fe treated cancer cells showed increased DAMPs release and result into intra-tumoral immune cell infiltration ( 104 ). Further combination with αPD-L1 checkpoint blockade led to better therapeutic effect.…”

Section: Nanotechnology Facilitates Immune Checkpoint Blockade Therapymentioning

confidence: 99%

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Liu

Xiang²,

Zheng³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) has gained unparalleled success in the treatment of colorectal cancer (CRC). However, undesired side effects, unsatisfactory response rates, tumor metastasis, and drug resistance still hinder the further application of ICB therapy against CRC. Advancing ICB with nanotechnology can be game-changing. With the development of immuno-oncology and nanomaterials, various nanoplatforms have been fabricated to enhance the efficacy of ICB in CRC treatment. Herein, this review systematically summarizes these recent nano-strategies according to their mechanisms. Despite their diverse and complex designs, these nanoplatforms have four main mechanisms in enhancing ICB: 1) targeting immune checkpoint inhibitors (ICIs) to tumor foci, 2) increasing tumor immunogenicity, 3) remodeling tumor microenvironment, and 4) pre-sensitizing immune systems. Importantly, advantages of nanotechnology in CRC, such as innovating the mode-of-actions of ICB, modulating intestinal microbiome, and integrating the whole process of antigen presentation, are highlighted in this review. In general, this review describes the latest applications of nanotechnology for CRC immunotherapy, and may shed light on the future design of ICB platforms.

show abstract

Section: Nanotechnology Facilitates Immune Checkpoint Blockade Therapymentioning

confidence: 99%

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Liu

Xiang²,

Zheng³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The earliest studies found that ferroptosis is mainly caused by an iron-dependent accumulation of lipid peroxidation, inactivation/depletion of anti-lipid peroxidation molecules, and increased mitochondrial membrane density. On this basis, several studies have made some progress in the non-surgical treatment of tumors by inducing ferroptosis of tumor cells through biomaterials ( Yang et al, 2021d ; Han et al, 2022 ). For example, Fu et al (2021) designed a mesoporous silica nanoplatform integrating doxorubicin and ferrate by assembling a solid-liquid phase change material of n -heneicosane, thus realizing the co-release of doxorubicin and ferrate under ultrasound (US).…”

Section: Other Bio-materialsmentioning

confidence: 99%

Multifunctional inorganic biomaterials: New weapons targeting osteosarcoma

Wang

Peng

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Osteosarcoma is the malignant tumor with the highest incidence rate among primary bone tumors and with a high mortality rate. The anti-osteosarcoma materials are the cross field between material science and medicine, having a wide range of application prospects. Among them, biological materials, such as compounds from black phosphorous, magnesium, zinc, copper, silver, etc., becoming highly valued in the biological materials field as well as in orthopedics due to their good biocompatibility, similar mechanical properties with biological bones, good biodegradation effect, and active antibacterial and anti-tumor effects. This article gives a comprehensive review of the research progress of anti-osteosarcoma biomaterials.

show abstract

“…Immune-stimulating nanodrugs (DHA and oxaliplatin) have been shown to induce ROS production in tumor cells, resulting in immunogenic programmed death and enhanced checkpoint blocking immunotherapy [ 289 ]. Recent literature suggests that DHA and pyropheophorbide-iron can produce and aggregate ROS to induce ferroptosis in an immunogenic manner, sensitizing non-immunogenic CRC, and can enhance the therapeutic effect of CRC anti-PD-L1 [ 290 ].…”

Section: Pathway Of Cell Deathmentioning

confidence: 99%

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Wang

Shen

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the leading causes of death worldwide. The 5-year survival rate is 90% for patients with early CRC, 70% for patients with locally advanced CRC, and 15% for patients with metastatic CRC (mCRC). In fact, most CRC patients are at an advanced stage at the time of diagnosis. Although chemotherapy, molecularly targeted therapy and immunotherapy have significantly improved patient survival, some patients are initially insensitive to these drugs or initially sensitive but quickly become insensitive, and the emergence of such primary and secondary drug resistance is a significant clinical challenge. The most direct cause of resistance is the aberrant anti-tumor drug metabolism, transportation or target. With more in-depth research, it is found that cell death pathways, carcinogenic signals, compensation feedback loop signal pathways and tumor immune microenvironment also play essential roles in the drug resistance mechanism. Here, we assess the current major mechanisms of CRC resistance and describe potential therapeutic interventions.

show abstract

Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy

Cited by 67 publications

References 56 publications

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Multifunctional inorganic biomaterials: New weapons targeting osteosarcoma

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Contact Info

Product

Resources

About